The regulatory network of the chemokine CCL5 in colorectal cancer

被引:12
|
作者
Zhang, Xin-Feng [1 ]
Zhang, Xiao-Li [1 ]
Wang, Ya-Jing [2 ]
Fang, Yuan [3 ]
Li, Meng-Li [4 ]
Liu, Xing-Yu [1 ]
Luo, Hua-You [1 ]
Tian, Yan [1 ]
机构
[1] Kunming Med Univ, Affiliated Hosp 1, Dept Gastrointestinal & Hernia Surg, 296 Xichang Rd, Kunming, Peoples R China
[2] Peoples Liberat Army Gen Hosp, Med Ctr 3, Dept Gen Surg, Beijing, Peoples R China
[3] Kunming Med Univ, Affiliated Hosp 1, Organ Transplant Dept, Kunming, Peoples R China
[4] Yunnan Univ, Honghui Hosp, Kunming, Peoples R China
基金
中国国家自然科学基金;
关键词
CCL5; colorectal cancer; immune regulation; immunotherapy; tumor microenvironment; MESENCHYMAL STEM-CELLS; CD8(+) T-CELLS; MAST-CELLS; TUMOR-STROMA; COLON-CANCER; CARCINOMA METASTASIS; DENDRITIC CELLS; PROGRESSION; RECEPTORS; ACTIVATION;
D O I
10.1080/07853890.2023.2205168
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The chemokine CCL5 plays a potential role in the occurrence and development of colorectal cancer (CRC). Previous studies have shown that CCL5 directly acts on tumor cells to change tumor metastatic rates. In addition, CCL5 recruits immune cells and immunosuppressive cells into the tumor microenvironment (TME) and reshapes the TME to adapt to tumor growth or increase antitumor immune efficacy, depending on the type of secretory cells releasing CCL5, the cellular function of CCL5 recruitment, and the underlying mechanisms. However, at present, research on the role played by CCL5 in the occurrence and development of CRC is still limited, and whether CCL5 promotes the occurrence and development of CRC and its role remain controversial. This paper discusses the cells recruited by CCL5 in patients with CRC and the specific mechanism of this recruitment, as well as recent clinical studies of CCL5 in patients with CRC. Key Messages CCL5 plays dual roles in colorectal cancer progression. CCL5 remodels the tumor microenvironment to adapt to colorectal cancer tumor growth by recruiting immunosuppressive cells or by direct action. CCL5 inhibits colorectal cancer tumor growth by recruiting immune cells or by direct action.
引用
收藏
页数:11
相关论文
共 50 条
  • [41] Identification of Fli-1 as a novel regulator of the inflammatory chemokine CCL5/RANTES
    Richard, Mara Lennard
    Sato, Shuzo
    Suzuki, Eiji
    Williams, Sarah
    Nowling, Tamara
    Zhaug, Xian
    JOURNAL OF IMMUNOLOGY, 2014, 192
  • [42] Chemokine CCL5/RANTES inhibition reduces myocardial reperfusion injury in atherosclerotic mice
    Braunersreuther, Vincent
    Pellieux, Corinne
    Pelli, Graziano
    Burger, Fabienne
    Steffens, Sabine
    Montessuit, Christophe
    Weber, Christian
    Proudfoot, Amanda
    Mach, Francois
    Arnaud, Claire
    JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 2010, 48 (04) : 789 - 798
  • [43] Oncogenic drivers of lung cancer induce production of CCL5 and recruitment of regulatory T-cells
    Franks, Elizabeth
    Halvorsen, Elizabeth C.
    Melese, Etienne
    Arun, Unni
    Collier, Jenna L.
    Harbourne, Bryant T.
    Oh, Min Hee
    Vivian, Lam
    Krystal, Gerry
    English, John C.
    Lam, Wan L.
    Lam, Stephen
    Abraham, Ninan
    Bennewith, Kevin L.
    Lockwood, William W.
    CLINICAL CANCER RESEARCH, 2018, 24 (17)
  • [44] OLIGOMERIZATION AND GLYCOSAMINOGLYCAN BINDING OF THE CHEMOKINE CCL5 MEDIATES EXPERIMENTAL LIVER INJURY IN MICE
    Nellen, A.
    Heinrichs, D.
    Fischer, P.
    Berres, M. -L.
    Proudfoot, A.
    Trautwein, C.
    Wasmuth, H. E.
    JOURNAL OF HEPATOLOGY, 2012, 56 : S156 - S157
  • [45] Interactions of the Chemokine CCL5/RANTES with Medium-Sized Chondroitin Sulfate Ligands
    Deshauer, Courtney
    Morgan, Ashli M.
    Ryan, Eathen O.
    Handel, Tracy M.
    Prestegard, James H.
    Wang, Xu
    STRUCTURE, 2015, 23 (06) : 1066 - 1077
  • [46] Role of myeloid-derived chemokine CCL5/RANTES at an early stage of atherosclerosis
    Jongstra-Bilen, Jenny
    Tai, Kelly
    Althagafi, Marwan G.
    Siu, Allan
    Scipione, Corey A.
    Karim, Saraf
    Polenz, Chanele K.
    Ikeda, Jiro
    Hyduk, Sharon J.
    Cybulsky, Myron I.
    JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 2021, 156 : 69 - 78
  • [47] PHARMACOLOGICAL ANTAGONISM OF THE CHEMOKINE CCL5 (RANTES) AMELIORATES EXPERIMENTAL LIVER FIBROSIS IN VIVO
    Berres, M. -L.
    Zaldivar, M. Moreno
    Koenen, R.
    Schmitz, P.
    Weber, C.
    Trautwein, C.
    Wasmuth, H. E.
    JOURNAL OF HEPATOLOGY, 2010, 52 : S355 - S355
  • [48] Downregulation of chemokine CCL5/RANTES gene expression in the NTS of SHR may be prohypertensive
    Gouraud, Sabine S.
    Waki, Hidefumi
    Bhulyan, Mohammad E. R.
    Takagishi, Miwa
    Kohsaka, Akira
    Paton, Julian F. R.
    Maeda, Masanobu
    JOURNAL OF PHYSIOLOGICAL SCIENCES, 2010, 60 : S167 - S167
  • [49] Oligomeric Structure of the Chemokine CCL5/RANTES from NMR, MS, and SAXS Data
    Wang, Xu
    Watson, Caroline
    Sharp, Joshua S.
    Handel, Tracy M.
    Prestegard, James H.
    STRUCTURE, 2011, 19 (08) : 1138 - 1148
  • [50] Attenuated chemokine Ccl5 activity in the NTS of SHR may be pro-hypertensive
    Gouraud, Sabine S.
    Waki, Hidefumi
    Bhuiyan, Mohammad E. R.
    Takagishi, Miwa
    Cui, He
    Kohsaka, Akira
    Paton, Julian F. R.
    Maeda, Masanobu
    NEUROSCIENCE RESEARCH, 2010, 68 : E166 - E167